These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 2787199)

  • 1. Functional analysis of cytotoxic cells in patients with acute nonlymphoblastic leukemia in complete remission.
    Trentin L; Pizzolo G; Feruglio C; Zambello R; Masciarelli M; Bulian P; Agostini C; Vinante F; Zanotti R; Semenzato G
    Cancer; 1989 Aug; 64(3):667-72. PubMed ID: 2787199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin 2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients. I. Feasibility of LAK generation in adult patients with active disease and in remission.
    Adler A; Chervenick PA; Whiteside TL; Lotzová E; Herberman RB
    Blood; 1988 Mar; 71(3):709-16. PubMed ID: 3257887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Susceptibility of human leukemia to allogeneic and autologous lymphokine-activated killer cell activity: analysis of 252 samples.
    Teichmann JV; Ludwig WD; Thiel E
    Nat Immun; 1992; 11(3):117-32. PubMed ID: 1392400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro susceptibility of acute leukemia cells to the cytotoxic activity of allogeneic and autologous lymphokine activated killer (LAK) effectors: correlation with the rate and duration of complete remission and with survival.
    Lauria F; Raspadori D; Rondelli D; Ventura MA; Foà R
    Leukemia; 1994 May; 8(5):724-8. PubMed ID: 8182932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inducibility of lymphokine activated killer (LAK) cells in patients with acute myelogenous leukaemia in complete remission and its clinical relevance.
    Archimbaud E; Bailly M; Doré JF
    Br J Haematol; 1991 Mar; 77(3):328-34. PubMed ID: 2012757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
    Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
    Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts.
    Baba M; Hasegawa H; Nakayabu M; Fukai K; Suzuki S
    J Clin Lab Immunol; 1993; 40(2):47-60. PubMed ID: 7932628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance of some leukemic blasts to lysis by lymphokine activated killer (LAK) cells.
    Panayotides P; Porwit A; Sjögren AM; Wasserman J; Reizenstein P
    Eur J Haematol; 1988 Apr; 40(4):362-7. PubMed ID: 3259192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A bispecific antibody enhances cytokine-induced killer-mediated cytolysis of autologous acute myeloid leukemia cells.
    Kaneko T; Fusauchi Y; Kakui Y; Masuda M; Akahoshi M; Teramura M; Motoji T; Okumura K; Mizoguchi H; Oshimi K
    Blood; 1993 Mar; 81(5):1333-41. PubMed ID: 8095165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant interleukin-2 activates peripheral blood lymphocytes from children with acute leukemia to kill autologous leukemic cells.
    Findley HW; Abdel Mageed A; Nasr SA; Ragab AH
    Cancer; 1988 Nov; 62(9):1928-31. PubMed ID: 3262410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ewing's sarcoma: ex vivo sensitivity towards natural and lymphokine-activated killing.
    Atzpodien J; Gulati SC; Shimazaki C; Bührer C; Oz S; Kwon JH; Kolitz JE; Clarkson BD
    Oncology; 1988; 45(6):437-43. PubMed ID: 3263598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytotoxic in vitro function in the lymphoproliferative disease of granular lymphocytes.
    Zambello R; Chisesi T; Agostini C; Trentin L; Masciarelli M; Gasparotto G; Vespignani M; Casorati G; Foa R; Semenzato G
    Clin Exp Immunol; 1987 Oct; 70(1):222-30. PubMed ID: 3121223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of LAK cells in vitro in patients with acute leukemia.
    Parrado A; Rodriguez-Fernandez JM; Casares S; Noguerol P; Plaza E; Parody R; Espigado I; de Blas JM; Garcia-Solis D
    Leukemia; 1993 Sep; 7(9):1344-8. PubMed ID: 8371585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Injury to autologous normal tissues and tumors mediated by lymphokine-activated killer (LAK) cells generated in vitro from peripheral blood mononuclear cells of glioblastoma patients.
    Fujimiya Y; Suzuki Y; Katakura R; Ohno T
    J Hematother; 1999 Feb; 8(1):29-37. PubMed ID: 10192299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expansion of natural killer cells with lytic activity against autologous blasts from adult and pediatric acute lymphoid leukemia patients in complete hematologic remission.
    Torelli GF; Guarini A; Maggio R; Alfieri C; Vitale A; Foà R
    Haematologica; 2005 Jun; 90(6):785-92. PubMed ID: 15951291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytotoxic in vitro function in patients with metastatic renal cell carcinoma before and after alpha-2b-interferon therapy. Effects of activation with recombinant interleukin-2.
    Feruglio C; Zambello R; Trentin L; Bulian P; Franceschi T; Cetto GL; Semenzato G
    Cancer; 1992 May; 69(10):2525-31. PubMed ID: 1568175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential role for non-HLA-restricted cytotoxic cells in the immune surveillance of acute leukemia.
    Archimbaud E; Campos L; Vila L; Thomas X
    Immunol Lett; 1993 Dec; 39(1):13-5. PubMed ID: 7511562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conjugate formation by leukemic blasts from acute myeloid leukemia with cytotoxic lymphocytes.
    Palucka AK; Porwit A; Reizenstein P
    Leuk Lymphoma; 1993 Nov; 11(5-6):427-33. PubMed ID: 7907248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin 2 induces human acute lymphocytic leukemia cells to manifest lymphokine-activated-killer (LAK) cytotoxicity.
    Kaufmann Y; Levanon M; Davidsohn J; Ramot B
    J Immunol; 1987 Aug; 139(3):977-82. PubMed ID: 3496395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro resistance of the brown Norway rat acute myelocytic leukemia (BNML) to lymphokine-activated killer activity.
    Gaiser JF; Kloosterman TC; Martens AC; Hagenbeek A
    Leukemia; 1993 May; 7(5):736-41. PubMed ID: 8483327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.